Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for rare respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company generates revenue through the sale of YUTREPIA (treprostinil) inhalation powder, a dry powder formulation designed using its proprietary PRINT technology to enhance deep lung delivery, and through a profit-sharing agreement with Sandoz for the sale of generic treprostinil injection in the United States. Liquidia operates through its wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC, formerly known as RareGen. Its pipeline includes L606, a liposomal formulation of treprostinil licensed from Pharmosa Biopharm Inc., which is being evaluated for PAH and PH-ILD. The company serves healthcare providers and patients in the United States, utilizing a targeted commercial field force to support the treatment of these conditions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage liquidia.com
Sector Healthcare IR page liquidia.com/investors
Tags
pulmonary arterial hypertension, pulmonary hypertension, interstitial lung disease, inhaled therapies, dry powder inhalers, treprostinil, drug delivery, rare diseases, cardiopulmonary disease, liposomal formulations, YUTREPIA, Treprostinil Injection, L606, PRINT technology, Liquidia Technologies Inc., Liquidia PAH LLC, RareGen, Pharmosa Biopharm Inc., Sandoz Inc.
Press page —

Metrics

Valuation  
Market cap $ 3.875B
Market cap (USD) $ 3.875B
P/E -35.99
PEG —
P/BV -152.37
P/S 6.23
P/OCF 11.96
P/FCF 13.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -113.0%
ROI -29.2%
ROIC -16.3%
Profit margin -43.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 427.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score -33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 158.32M 13.996M 17.488M 15.935M 12.853M 739.628K 8.072M 2.707M 7.258M
Net profit -68.924M -130.394M -78.502M -41.015M -34.579M -59.763M -47.583M -53.136M -29.154M
Free cash flow -40.022M -98.371M -42.854M -29.18M -34.143M -54.897M -50.133M -32.701M -26.834M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 34.49 11.76 12.03 6.37 4.87 2.95 4.27 21.66 —
Price performance 12m 1.93 -0.02 0.89 0.31 0.65 -0.31 -0.8 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.62M 272,557 — 0.00 2.99M 5.02M 4.06M 2.72M 54.1M
↳ YoY growth -83.2% +67.8% -19.1% -33.0% +1,889.4%
↳ 5y CAGR +25.3% +71.6%
Borrowings, current (USD) — 15.6M 316,906 5.59M 0.00 — — — — —
Borrowings, non-current (USD) — 5.56M 11.6M 10.3M 10.3M 10.4M 19.9M — — —
Lease liabilities (USD) — — 6.66M 8.54M 6.85M 5.67M 4.58M 3.5M 6.94M —
Cash and deposits (USD) 1.44M 3.42M 39.5M 55.8M 65.3M 57.5M 93.3M 83.7M 176M 191M
Intangible assets (USD) — — — 0.00 5.53M 4.39M 3.73M 3.43M 3.16M 2.95M
Right-of-use assets (USD) — — 3.99M 2.82M 2.65M 2.41M 2.1M 1.7M 4.19M 3.95M
Net debt (borrowings + leases - cash) (USD) — 17.7M -27.6M -31.4M -48.2M -41.4M -68.8M — — —
Cash flow detail
Operating cash flow (USD) — -24.3M -31.8M -48.3M -54.1M -34M -28.6M -41.6M -93.4M -35.7M
Purchases of property, plant and equipment (USD) — -2.54M -870,943 -1.85M -752,086 -107,220 -592,000 -1.29M -4.95M -4.34M
Change in receivables (cash effect) (USD) — -328,458 1.35M 272,557 0.00 -2.99M -2.03M 956,000 1.34M -51.4M
Change in inventories (cash effect) (USD) — — — — — — — — -241,000 -23M
Change in payables (cash effect) (USD) — 1.87M -1.28M 294,514 -297,160 -7.56M 814,000 -1.15M 2.33M -2.59M
Interest paid (cash effect) (USD) — -313,390 -1.09M -887,038 -820,889 -423,230 -1.63M -360,000 — —
Income taxes paid (cash effect) (USD) — — — — — — — 0.00 0.00 0.00
Share-based compensation (USD) — 514,092 2.2M 3.38M 3.95M 6.75M 9.3M 10.1M 18.8M 29.5M
Operating cash flow before change in receivables (USD) — -24M -33.2M -48.6M -54.1M -31M -26.6M -42.5M -94.8M 15.7M
Free cash flow (OCF - PPE - intangibles) (USD) — -26.8M -32.7M -50.1M -54.9M -34.1M -29.2M -42.9M -98.4M -40M
Income detail
Research and development expense (USD) — 24.8M 28.7M 40.5M 32.2M 20.5M 19.4M 43.2M 47.8M 39.3M
↳ 5y CAGR -4.7% +8.5% +3.4% +4.0%
Total comprehensive income (USD) — -29.2M -53.1M -47.6M — — — — — —
Comprehensive income to owners (USD) — -29.2M -53.1M -47.6M — — — — — —
Reported Aug 14, 2018 Feb 26, 2019 May 2, 2019 Mar 25, 2021 May 13, 2021 Mar 17, 2022 Mar 20, 2023 Mar 5, 2026 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 12, 2026, the Board of Directors of Liquidia Corporation, a Delaware corporation (the “Company”), appointed Russell Schundler as the Company’s Chief Strategy Officer and General Counsel, effective November 16, 2026 (the “Effective Date”). Mr. Schundler has served as the Company’s General Counsel since March 2021. Effective upon Mr. Schundler’s appointment as Chief Strategy Officer and General Counsel, his annual base compensation was increased to $625,000 and his target bonus was increased to 60% of his annual base compensation. In addition, Mr. Schundler was granted a number of restricted stock units (the “RSUs”) under the Company’s 2020 Long-Term Incentive Plan (the “Plan”) equal to $500,000 divided by the Fair Market Value (as defined in the Plan) of a share of the Company’s common stock as of the Effective Date. The RSUs (i) are subject to the terms of the Plan and the form of award agreement and (ii) vest as follows: 25% of the grant will become vested on January 11, 2028, and the balance will become vested in equal quarterly installments over the following three years, subject to Mr. Schundler’s continuous employment with the Company on each such vesting date.

· YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026

· October 2026 total patient shipments reached their highest monthly level since launch

· Resolved all litigation with United Therapeutics through a global settlement, securing continuity of care for all patients treated with YUTREPIA

· Recorded net loss of $236.3 million reflects a $389.7 million litigation settlement charge

· Fifth consecutive quarter of increasing non-GAAP, adjusted EBITDA to $140.5 million

· Increased cash and cash equivalents to $396.1 million prior to settlement payments

· Granted Fast Track designation to YUTREPIA for the treatment of SSc-RP and initiated RE-WARM, a Phase 2 randomized open-label dose-finding study

MORRISVILLE, N.C., November 10, 2026 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m.

November 3, 2026

PDF Version

MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To learn more about Liquidia, please visit www.liquidia.com.

Prompts

Liquidia Corporation (ticker LQDA), listed in United States.

Company History

Date Change Detail
Aug 5, 2020 Renamed LIQUIDIA TECHNOLOGIES INC → LIQUIDIA CORP

ETFs Holding Liquidia Corporation

ETF Weight in ETF Shares Market value As of
JSML 1.30% 56,094 $ 4.718M Jul 31, 2026
JSMD 1.26% 157,623 $ 13.258M Jul 31, 2026
FSCC 0.97% 51,507 $ 3.511M Aug 31, 2026
FSEG 0.57% 409 $ 32.61K Jun 30, 2026
AFSM 0.56% 14,496 $ 817.14K Nov 16, 2026
FTKI 0.56% 2,508 $ 141.376K Nov 16, 2026
EHLS 0.42% 4,009 $ 225.987K Nov 17, 2026
ESSC 0.36% 1,547 $ 130.118K Jul 31, 2026
FESM 0.30% 214,691 $ 17.117M Jun 30, 2026
HELX 0.25% 871 $ 69.445K Jun 30, 2026
VFMO 0.14% 39,128 $ 2.667M Aug 31, 2026
AFMC 0.13% 5,854 $ 329.99K Nov 16, 2026
MKTN 0.11% 1,537 $ 122.545K Jun 30, 2026
SHRT 0.09% 200 $ 11.274K Nov 17, 2026
FTLS 0.07% 31,058 $ 0.00 Nov 16, 2026
DFAS 0.04% 222,059 $ 12.906M Nov 12, 2026
IALT short -0.03% -39,020 $ -2.2M Nov 16, 2026
MSSM 0.03% 2,896 $ 197.42K Aug 31, 2026
JSTC 0.02% 983 $ 55.412K Nov 17, 2026
GVLU 0.02% 819 $ 46.167K Nov 17, 2026
DCOR 0.00% 1,970 $ 114.496K Nov 12, 2026
NTRL 0.00% 4,562 $ 0.00 Nov 16, 2026